Low cancer clinical trial (CCT) enrollment may contribute to survival disparities affecting adolescents and young adults (AYAs) (ages 15-39 years). The objective of this study was to evaluate whether differences in CCT availability related to treatment site could explain the low CCT enrollment. METHODS: This prospective, observational cohort study was conducted at an academic children's hospital and its affiliated but geographically separated adult cancer hospital within a National Cancer Institute-designated Comprehensive Cancer Center. For consecutive, newly diagnosed AYA patients, it was determined whether an appropriate CCT existed nationally, was available at the treatment site, and was used for enrollment. Proportions of AYAs in these categories were compared between sites using the chi-square test. RESULTS: One hundred fifty-two consecutive AYA patients were included from the children's hospital (n = 68; ages 15-20 years) and the adult cancer hospital (n = 84; ages 18-39 years 
INTRODUCTION
Lagging improvement in survival between younger and older patients is prominent among the many challenges facing adolescents and young adults (AYAs) (ages 15-39 years) with cancer, as identified by the US National Cancer Institute (NCI). [1] [2] [3] The cause of this lower survival improvement is likely multifactorial, but low participation of AYAs in NCIsponsored cancer clinical trials (CCTs) is considered a key contributor. 4 Low CCT enrollment also prevents AYAs from gaining access to promising investigational therapies, providing biospecimens essential for basic and translational research, and offering their unique perspective in studies of supportive care, quality of life, and other nonsurvival endpoints. 5 There are multiple reports of low CCT enrollment for AYAs in the literature. Compared with approximately 40% to 60% of children aged <15 years, only 10% to 20% of early AYAs (ages 15-21 years) and <10% of older AYAs participate in CCTs. 1, 4, [6] [7] [8] [9] At our own institution, 15% of early AYAs treated at our children's hospital were enrolled onto
Cancer October 15, 2018 clinical trials compared with <7% of older AYAs treated at our adult cancer hospital. 8 Reasons for lower CCT enrollment of AYAs are not well understood. The factors associated with low CCT enrollment include suboptimal insurance, low socioeconomic status, distance to the cancer center, older age, type of cancer specialist, treatment at nonacademic institutions, and clinicians who do not participate in NCI-sponsored CCTs. 7, 10, 11 Limited availability of CCTs for AYAs is another potential factor often speculated to be of major importance. 7, 9, 12, 13 In theory, a lack of CCTs would be decisive in that, without an available trial, enrollment is impossible. 5 However, we recently conducted a prospective, observational cohort study of CCT availability and enrollment among early AYAs within our academic children's hospital. The prospective, case-level methodology we used allowed real-time ascertainment of individual patient eligibility in relation to confirmed CCTs that were open at our institution. Unexpectedly, we discovered that, although CCT enrollment was significantly lower for early AYAs compared with children, 14 CCT availability was no different. Our findings suggested that, in the setting of a children's hospital, provider-level and patient/family-level barriers involving priorities, knowledge, beliefs, and attitudes were more critical than CCT availability.
Yet CCT enrollment barriers may not be the same for early AYAs and older AYAs because of differences in lifestage and the type of treating institution. In addition, it is commonly hypothesized (although without compelling data) that a major cause of low enrollment is that CCT availability is lower for older than for younger AYAs. 7, 15 To explore these potential differences, we conducted the current prospective study comparing front-line therapeutic CCT national existence, institutional availability, and utilization for enrollment among AYAs diagnosed at either the academic children's hospital or the adult cancer hospital within our NCI-designated Comprehensive Cancer Center. The primary study objective was to compare the proportions of AYAs at each location for whom an appropriate CCT existed, was available locally, and was used for enrollment. Our overall hypothesis was that all 3 components would be significantly lower among AYAs at the adult cancer hospital.
MATERIALS AND METHODS

Study Design, Setting, and Case Ascertainment
This prospective, observational cohort study was conducted at 2 sites that are part of the University of Southern California (USC) Norris Comprehensive Cancer Center: Children's Hospital Los Angles (CHLA) (an academic children's hospital) and the Norris Cancer Hospital (NCH) (an adult cancer hospital). Although affiliated, these 2 sites are clinically and administratively distinct and are located on separate campuses about 6 miles apart. In general, AYAs aged 15 to 21 years are treated at CHLA, whereas AYAs aged 18 to 39 years are treated at NCH. The 2 sites have a relationship as members of an over-arching AYA program, but a coordinated CCT enrollment mechanism for AYAs has not been implemented to date. Finally, the institutions use separate Institutional Review Boards (IRBs).
To confirm the feasibility of our methods, we first conducted a pilot study of 10 patients at CHLA and 10 patients at NCH, all of whom are included in the current cohort. Case ascertainment was site-specific to allow for concurrent, prospective identification of newly diagnosed patients. At CHLA, all consecutive pathology reports from patients aged 15 to 21 years were screened in real time by collaborating pediatric pathology fellows (H.T., J.S.) and were transmitted to the principal investigator (S.M.T.) with name, medical record number, and final pathology diagnosis. Pathology reports were reviewed by S.M.T. and disregarded if they represented pathology-only consultations for patients who did not receive cancer care at CHLA or pathology specimens from second surgeries for patients already included in this study. The remaining pathology reports were used to identify unique patients aged 15 to 21 years who had a first diagnosis of cancer and had cancer treatment initiated at CHLA. At NCH, Cancer Registry staff identified newly diagnosed patients aged 15 to 39 years and transmitted their names, medical record numbers, and cancer diagnoses to S.M.T. every 2 weeks. S.M.T. reviewed the associated medical records to identify unique patients aged 15 to 39 years who had a first diagnosis of cancer and initiated cancer treatment at NCH. At both sites, patients with relapsed cancer, a subsequent malignant neoplasm, or a history of previously starting cancer treatment elsewhere were excluded.
For each eligible patient, pertinent demographic (age, sex, and race/ethnicity) and disease-related (cancer diagnosis, stage, grade, risk group, and relevant genomics) information was abstracted from the medical record. Patients were classified by treatment site. Both the CHLA and USC IRBs approved this study with a waiver for informed consent, because only anonymous data were collected, and there was no patient contact.
Cancer October 15, 2018 Determination of CCT Existence, Availability, and Enrollment Status At both sites, the following methods were applied for each eligible patient. For purposes of this study, clinical trial existence was operationalized as a CCT appropriate for the patient's age, diagnosis, and stage/risk-group registered nationally on clinicaltrials.gov (US National Library of Medicine, National Institutes of Health, Bethesda, MD) and listed as open and recruiting. Clinical trial availability was operationalized as an existing CCT that was IRB-approved, activated, and open to enrollment at the site when that patient was diagnosed. Clinical trial enrollment was operationalized as the patient being successfully entered onto the CCT according to standard procedures of the respective clinical trials support office.
For each patient, the existence of a CCT was determined by S.M.T. within 2 weeks of receiving the diagnosis by searching clinicaltrials.gov for a relevant CCT. The 2-week timeframe was established because trial sponsors are required to post updates on clinicaltrials.gov within 4 weeks of changes in enrolling status. The diagnosis was entered into the search term area with studies limited to those open and recruiting, interventional, and available in the United States. If a trial was so identified, then patient-specific clinical information (eg, histology, stage, grade, risk group, genomic status, and other characteristics) was used to determine the patient's specific eligibility for that trial. Those confirmed as eligible were thus classified as having an existing CCT. Trial-specific data available on clinicaltrials.gov were recorded, including the National Clinical Trial (NCT) identification number, phase, categorical type (eg, National Clinical Trials Network [NCTN] group, other national collaborative group, multicenter collaboration, industry, or institutional), the specific sponsor, and the date the trial opened. Patients with an existing CCT were then assessed for availability of and enrollment on the CCT. Chart review was reassessed weekly until treatment was initiated to capture any CCTs that may have been activated after diagnosis but before therapy initiation, allowing for just-in-time activation of CCTs.
For patients who had more than 1 applicable trial listed on clinicaltrials.gov but none available at their treatment site, only 1 trial was recorded as existing using the following hierarchy: NCTN, other national collaborative group, multicenter collaboration, industry-sponsored, or institutional.
Statistical Analysis
Descriptive statistics were used to characterize the sample. Differences in demographics, CCT existence, CCT availability, and CCT enrollment among AYAs treated at CHLA versus at NCH were evaluated using the chi-square test of proportions, and a P value < .05 was defined as significant. SPSS statistical software was used for all analyses (version 24.0; IBM Corporation, Armonk, NY). 16 
RESULTS
In total, 238 unique AYA patients were screened for eligibility (CHLA, n = 92; NCH, n = 146) between November 1, 2015 and December 1, 2016, Of these, 86 AYAs were excluded for having relapsed disease or starting treatment before referral (CHLA, n = 24; NCH, n = 62) (Fig. 1 ). There were no patients with second malignant neoplasms.
Patient Characteristics
In total, 152 AYAs were included in this study (CHLA, n = 68; NCH, n = 84) ( Table 1 ). The median ages of AYAs at CHLA and NCH were 17 years (range, 15-20 years) and 31 years (range, 18-39 years), respectively. There were 22 AYAs in the group ages 18 to 21 years who could have been treated at either site (CHLA, n = 18; NCH, n = 4). Distribution by sex and race/ethnicity was similar across groups. Whereas leukemia was the most common diagnosis at CHLA, solid tumors predominated at NCH, particularly carcinomas.
CCT Existence, Availability, and Enrollment Proportions
The proportions of CCT existence, availability, and enrollment were compared between AYAs treated at CHLA versus NCH (Fig. 2) . The proportions of AYAs In total, 30 AYAs had a trial available to them but did not enroll (CHLA, n = 22; NCH, n = 8). At both sites, patient age and ethnicity were similar between those who did and did not enroll; however, males were more likely not to enroll at CHLA than at NCH (14 of 22 [63.6%] vs 6 of 8 [75%], respectively). Nonenrolled AYAs at CHLA had the following diagnoses: ALL (n = 9), Hodgkin lymphoma (n = 5), acute myeloid leukemia (n = 4), acute promyelocytic leukemia (n = 2), Ewing sarcoma (n = 1), and synovial sarcoma (n = 1). This differed at NCH, where nonenrolled AYAs had the following diagnoses: testicular carcinoma (n = 5), cervical carcinoma (n = 2), and malignant peripheral nerve sheath tumor (n = 1).
CCT Characteristics
The characteristics of CCTs that existed, were available, and were used for enrollment at the 2 sites are listed in Table 2 . At the national level, 35 unique trials existed for AYAs in this study. Of these, 8 existed for AYAs only at CHLA, 21 existed for AYAs only at NCH, and 6 existed for AYAs across sites. Of the trials that existed nationally, 8 of 14 (57.1%) were available at CHLA, and only 4 of 27 (14.8%) were available at NCH. Of the 6 trials that existed nationally for AYAs across sites, 3 were available only at CHLA, 1 was available only at NCH, 1 was available at both sites, and 1 was available at neither site. The single CCT available at both sites was a Children's Oncology Group study for nonrhabdomyosarcomatous soft tissue sarcoma that was opened at NCH through the NCI Cancer Trials Support Unit (CTSU) mechanism (available at: www.ctsu.org, accessed August 10, 2018). The 8 CCTs available at CHLA included all 4 diagnostic categories (leukemia, lymphoma, brain tumors, and nonbrain solid tumors), whereas the 4 CCTs available at NCH were only for nonbrain solid tumors. At CHLA, all available CCTs were phase 3 and were sponsored by the Children's Oncology Group. In contrast, of the 4 available CCTs at NCH, 1 each was phase 1, 2, 2/3, and 3; 3 of these were sponsored by adult-focused NCTN groups; and 1 was a multi-institutional collaboration. We note that none of the available CCTs at either site were industry-sponsored.
DISCUSSION
The objective of this study was to determine the existence, availability, and utilization of CCTs for enrollment of AYAs treated at either an academic children's hospital Cancer October 15, 2018 (CHLA) or an affiliated adult cancer hospital (NCH). Our findings shed much-needed light on the CCT enrollment fate of AYAs with a first diagnosis of cancer. Although CCTs existed nationally for more than onehalf of our AYAs at both sites, CCTs were available for only one-third as many AYAs at NCH. Although the overall low CCT enrollment of approximately 10% at both sites was not unexpected and was consistent with previous reports, 1,8,13,17 our findings of national-level similarity in CCT existence, but site-level disparity in CCT availability, are novel. The findings are significant because they demonstrate the need to account for treatment setting when considering solutions for the difficult problem of low CCT enrollment of AYAs. To our knowledge, this is the first prospective study to compare CCT existence and availability in explaining low CCT enrollment among AYAs treated at pediatric or adult cancer hospitals. Cancer October 15, 2018 This study adds to the scant published research concerning causes for low AYA enrollment onto CCTs. In addition to our recent prospective study of CCT availability within a children's hospital, 14 we are aware of only 3 other reports of CCT availability for AYAs: 2 from 1 cancer center using internal data 13, 15 and 1 from the NCI using population-based estimates. 18 All 3 of those studies were retrospective, detected relatively small effects, and yielded mixed results. In the current report, we have more definitively compared CCT existence and availability for AYAs who received treatment concurrently at either a pediatric hospital (CHLA) or an adult cancer specialty hospital (NCH). The CCT enrollment pathway can be viewed as a linear process that first requires having CCTs existing at the national level, which are then made available at the institutional level, offered by the provider, and finally accepted by the patient/family. 5 CCT existence and availability as potential upstream enrollment barriers are particularly crucial because, without available CCTs, downstream barriers at the provider and patient/family levels become irrelevant. In our recent study comparing CCT availability and enrollment for children versus early AYAs (aged 15-21 years) who received treatment in an academic children's hospital, we observed similar CCT availability but significantly lower enrollment of early AYAs.
14 Whereas those results suggested that patient/family-level and provider-level barriers were more important for AYAs in the pediatric setting, our current study demonstrates unequivocally that low CCT availability was the major barrier for AYAs in our adult cancer hospital, irrespective of target cancer, trial phase, or sponsor of existing CCTs. However, it is important to note that the proportion of AYAs who enrolled on a CCT when 1 was available was actually higher at our adult cancer hospital than at the children's hospital. Although our study was not designed to assess physician motivation or other downstream barriers and facilitators of enrollment on available CCTs, it is clear from our data that distinctly different explanations may account for low CCT enrollment of AYAs, depending on their treatment setting.
Appreciating alternative causes for low CCT enrollment is important both for informing future research and for developing potential solutions. 5 In our current study, CCT existence clearly was not the primary barrier: indeed, twice as many CCTs existed for AYAs at the adult cancer hospital than at the children's hospital. The striking disparity in CCT availability at our adult site appears to have reflected a focus on solid tumors and early phase trials (Table 2 ). This diagnostic specificity may not be altogether inappropriate given that three-quarters of those AYAs had nonhematologic cancers (Table 1) . However, this emphasis on new-agent studies may not serve well the population of AYAs with newly diagnosed cancer, for whom only 1 phase 3 CCT was available. In this respect, the 5 AYAs diagnosed with ALL at our adult site would have benefited from having access to the appropriate CCT available at our children's hospital. Now that these important gaps have been identified, further research has been initiated to elucidate the factors influencing institutional prioritization of CCTs and the development of effective mechanisms for enrolling AYAs across affiliated sites like ours.
The setting and design of our study afforded several strengths and some limitations. A significant strength was prospective, concurrent case ascertainment at 2 affiliated sites combined with real-time, case-linked evaluation of CCT existence and availability. This provided a level of accuracy difficult to achieve retrospectively, because CCTs open and close to enrollment over time, and detailed clinical information is needed to assess trial-specific eligibility fully for individual patients. The volume and heterogeneity of patients made it feasible to conduct our study at 2 sites over a relatively short period. To identify patients in real time, different methods of case ascertainment were needed at the 2 sites, which could have introduced different selection biases in the 2 cohorts. However, there were sizeable numbers of relapsed/refractory patients at NCH that were not included. Therefore, our focus on patients with first cancers prevents commenting on CCT availability for relapsed cancer, which could be important for AYAs, who often have high-risk disease. In addition, our results may not be generalizable to community-based hospitals, where most AYAs receive treatment, or to academic hospitals that serve the full AYA age spectrum at a single site. Research investigating CCT availability is needed in both of these populations. Because our study was designed to assess only CCT availability and enrollment, reasons for nonenrollment onto available CCTs cannot be assessed from these data.
Nonetheless, several insights about the relative importance of CCT availability for AYAs can be gained from our data. First, because CCT existence was similar at both sites, simply opening more trials nationally, as has been suggested, 7, 12, 13 is unlikely to alter overall AYA enrollment. Low institutional CCT availability appears to be the more promising target. However, solutions for this may require a mix of site-specific and general measures. For example, although our adult site emphasized solid tumors and new agents, centers prioritizing phase 3 trials for newly diagnosed patients with more prevalent Cancer October 15, 2018 AYA diagnoses (including leukemia and lymphoma) would offer greater CCT availability and theoretically would have the greatest impact on improving outcomes. This should be done in a site-specific manner, such that existing CCTs are opened for the most common AYA cancers referred to that institution. Conversely, certain barriers to opening CCTs may apply across adult centers, such as the financial burden of conducting NCTN studies compared with industry trials (although it is notable that existing industry CCTs were equally unavailable for AYAs in our study). 19 Thus, strategies that reduce the burden for institutions in opening AYA-relevant phase 3 trials are likely to be impactful. In this regard, the NCI Central IRB approval process has lessened the burden for scientific review at the local sites.
Finally, institutions that have relatively seamless clinical research operations are at a distinct advantage when it comes to enrolling the full age spectrum of AYAs onto CCTs. On-site partnerships across pediatric and adult oncology, coupled with sharing 1 electronic health record and IRB for studies that cannot use the NCI Central IRB, would likely facilitate CCT enrollment. Such partnering could include joint tumor boards that identify AYAs who are eligible for CCTs across institutions and the development of mechanisms to facilitate their enrollment, such as reciprocal cross-group affiliation of medical and pediatric oncologists and clinical cooperation in the delivery of protocol therapy. The NCI CTSU provides a just-in-time mechanism for accomplishing cross-group enrollment, which is the rapid activation of CCTs for patients who present with rare diagnoses. 20 However, not all CCTs are available through the CTSU. Furthermore, treatment sites still must have the resources and motivation to open those CCTs that are available through the CTSU. In theory, the development of an AYA program could heighten institutional awareness of these issues, garner additional resources, provide educational opportunities about the importance of trial enrollment in this population, and foster collaborations to overcome these barriers. 21 Even then, as our experience illustrates, the challenges remain daunting and highlight the need for having accurate CCTs availability and enrollment data to address the most salient barriers.
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